Na+ Currents in Cardioprotection: Better to Be Late

被引:14
作者
Le Grand, Bruno [2 ]
Pignier, Christophe [2 ]
Letienne, Robert [2 ]
Colpaert, Francis [3 ]
Cuisiat, Florence [1 ]
Rolland, Francoise [1 ]
Mas, Agnes [1 ]
Borras, Maud [1 ]
Vacher, Bernard [1 ]
机构
[1] Ctr Rech Pierre Fabre, Med Chem Div 1, F-81106 Castres, France
[2] Ctr Rech Pierre Fabre, Cardiovasc Div 2, F-81106 Castres, France
[3] Toulouse ISTMT 2, F-31400 Toulouse, France
关键词
PERSISTENT SODIUM CURRENT; ACUTE CORONARY SYNDROMES; ONE-POT SYNTHESIS; MYOCARDIAL-INFARCTION; ISCHEMIA-REPERFUSION; ANTIANGINAL AGENT; TROPONIN-I; RANOLAZINE; ANGINA; HEART;
D O I
10.1021/jm900296e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report the discovery of a selective, potent inhibitor of the late current mediated by the cardiac isoform of the sodium channel (Nav 1.5). The compound, 3,4-dihydro-N-[(2S)-3-[(2-hydroxy-3-methylphenyl)thio]-2-methylpropyl]-2H-(3R)-1,5-benzoxathiepin-3-amine (2d) (F 15741), blocks the late component of the Na+ currents and greatly reduces veratridine- or ischemia-induced contracture in isolated tissue and whole heart. The cardioprotective action of 2d was further established in a model of myocardial infarction in the pig in which 2d prevents ischemia-reperfusion damage after 60 min of coronary occlusion and 48 h reperfusion. Under these experimental conditions, only 2d and cariporide reduce infarct size. Remarkably, myocardial protection afforded by 2d occurs in the absence of hemodynamic effects. These data expand the therapeutic potential of late I-Na blockers and suggest that 2d could be useful in pathologies for which pharmacological treatments are not yet available.
引用
收藏
页码:4149 / 4160
页数:12
相关论文
共 79 条
[1]   A review on the use of sodium triacetoxyborohydride in the reductive amination of ketones and aldehydes [J].
Abdel-Magid, Ahmed F. ;
Mehrman, Steven J. .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2006, 10 (05) :971-1031
[2]   Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation [J].
Abou-Khalil, B ;
Ge, Q ;
Desai, R ;
Ryther, R ;
Bazyk, A ;
Bailey, R ;
Haines, JL ;
Sutcliffe, JS ;
George, AL .
NEUROLOGY, 2001, 57 (12) :2265-2272
[3]   Alternative Pharmacological Interventions that Limit Myocardial Infarction [J].
Andreadou, I. ;
Iliodromitis, E. K. ;
Koufaki, M. ;
Farmakis, D. ;
Tsotinis, A. ;
Kremastinos, D. Th. .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (30) :3204-3213
[4]   Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties [J].
Antzelevitch, C ;
Belardinelli, L ;
Zygmunt, AC ;
Burashnikov, A ;
Di Diego, JM ;
Fish, JM ;
Cordeiro, JM ;
Thomas, G .
CIRCULATION, 2004, 110 (08) :904-910
[5]   Different pathways for sodium entry in cardiac cells during ischemia and early reperfusion [J].
Baetz, D ;
Bernard, M ;
Pinet, C ;
Tamareille, S ;
Chattou, S ;
El Banani, H ;
Coulombe, A ;
Feuvray, D .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 242 (1-2) :115-120
[6]   MOLECULAR MECHANISM FOR AN INHERITED CARDIAC-ARRHYTHMIA [J].
BENNETT, PB ;
YAZAWA, K ;
MAKITA, N ;
GEORGE, AL .
NATURE, 1995, 376 (6542) :683-685
[7]   MODULATION OF THE INFLAMMATORY RESPONSE IN EXPERIMENTAL MYOCARDIAL-INFARCTION [J].
BOHLE, RM ;
PICH, S ;
KLEIN, HH .
EUROPEAN HEART JOURNAL, 1991, 12 :28-31
[8]  
CABIDDU S, 1969, GAZZ CHIM ITAL, V99, P1095
[9]   Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses [J].
Cannon, SC .
KIDNEY INTERNATIONAL, 2000, 57 (03) :772-779
[10]   Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina - A randomized controlled trial [J].
Chaitman, BR ;
Pepine, CJ ;
Parker, JO ;
Skopal, J ;
Chumakova, G ;
Kuch, J ;
Wang, WD ;
Skettino, SL ;
Wolff, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (03) :309-316